RT Journal Article
SR Electronic
T1 Nanovesicles derived from iron oxide nanoparticles–incorporated mesenchymal stem cells for cardiac repair
JF Science Advances
JO Sci Adv
FD American Association for the Advancement of Science
SP eaaz0952
DO 10.1126/sciadv.aaz0952
VO 6
IS 18
A1 Lee, Ju-Ro
A1 Park, Bong-Woo
A1 Kim, Jonghoon
A1 Choo, Yeon Woong
A1 Kim, Han Young
A1 Yoon, Jeong-Kee
A1 Kim, Hyeok
A1 Hwang, Ji-Won
A1 Kang, Mikyung
A1 Kwon, Sung Pil
A1 Song, Seuk Young
A1 Ko, In Ok
A1 Park, Ji-Ae
A1 Ban, Kiwon
A1 Hyeon, Taeghwan
A1 Park, Hun-Jun
A1 Kim, Byung-Soo
YR 2020
UL http://advances.sciencemag.org/content/6/18/eaaz0952.abstract
AB Because of poor engraftment and safety concerns regarding mesenchymal stem cell (MSC) therapy, MSC-derived exosomes have emerged as an alternative cell-free therapy for myocardial infarction (MI). However, the diffusion of exosomes out of the infarcted heart following injection and the low productivity limit the potential of clinical applications. Here, we developed exosome-mimetic extracellular nanovesicles (NVs) derived from iron oxide nanoparticles (IONPs)–incorporated MSCs (IONP-MSCs). The retention of injected IONP-MSC–derived NVs (IONP-NVs) within the infarcted heart was markedly augmented by magnetic guidance. Furthermore, IONPs significantly increased the levels of therapeutic molecules in IONP-MSCs and IONP-NVs, which can reduce the concern of low exosome productivity. The injection of IONP-NVs into the infarcted heart and magnetic guidance induced an early shift from the inflammation phase to the reparative phase, reduced apoptosis and fibrosis, and enhanced angiogenesis and cardiac function recovery. This approach can enhance the therapeutic potency of an MSC-derived NV therapy.